VEA
RNAC icon

Virtus ETF Advisers’s Cartesian Therapeutics RNAC Stock Holding History

Virtus ETF Advisers’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,533
Closed -$63.3K – 723
2024
Q4 		$63.3K Buy
+3,533
New +$71.5K 0.03% 433
2022
Q2 		– Sell
-1,641
Closed -$61K – 468
2022
Q1 		$61K Sell
1,641
-97
-6% -$6.07K 0.03% 358
2021
Q4 		$170K Buy
1,738
+324
+23% +$34.9K 0.06% 286
2021
Q3 		$177K Sell
1,414
-74
-5% -$8.94K 0.08% 298
2021
Q2 		$187K Sell
1,488
-1,690
-53% -$201K 0.08% 377
2021
Q1 		$431K Buy
3,178
+56
+2% +$6.95K 0.18% 168
2020
Q4 		$284K Sell
3,122
-712
-19% -$61.7K 0.12% 239
2020
Q3 		$285K Sell
3,834
-523
-12% -$40.1K 0.15% 235
2020
Q2 		$371K Buy
+4,357
New +$395K 0.18% 235
2018
Q4 		– Sell
-1,282
Closed -$598K – 370
2018
Q3 		$598K Sell
1,282
-941
-42% -$378K 0.06% 103
2018
Q2 		$884K Buy
+2,223
New +$789K 0.78% 13

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Virtus ETF Advisers's RNAC Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Cartesian Therapeutics (RNAC) in Q1 2025, closing a stake of 3,533 shares — an estimated $63.3K sold.

Virtus ETF Advisers first reported a position in RNAC in Q2 2018 and held it in 11 quarters. The position peaked at $884K in Q2 2018. 72 funds tracked by Wall St. Rank hold RNAC as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Cartesian Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,533 Cartesian Therapeutics shares in Q1 2025, an estimated $63.3K.
  • Virtus ETF Advisers first reported a position in Cartesian Therapeutics in Q2 2018 and held it in 11 quarters.
  • Virtus ETF Advisers's Cartesian Therapeutics position peaked at $884K in Q2 2018.
  • 72 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.